Professor Chris Goodnow, Medical Research Director at the Garvan Institute, whose scientists have engineered human antibodies that attack SARS-CoV-2. Once optimised, the viral therapy will be tested in human clinical trials by the Kirby Institute and may provide immunity to the coronavirus for both treatment and prevention. Professor Goodnow says he is “very optimistic” that the antibodies would form the basis of a therapy. The first phase of human clinical trials could start towards the later part of this year.

<p>Professor Chris Goodnow, Medical Research Director at the Garvan Institute, whose scientists have engineered human antibodies that attack SARS-CoV-2.&nbsp;Once optimised, the viral therapy will be tested in human clinical trials by the Kirby Institute and may provide immunity to the coronavirus for both treatment and prevention.&nbsp;Professor Goodnow says he is &ldquo;very optimistic&rdquo; that the antibodies would form the basis of a therapy. The first phase of human clinical trials could start towards the later part of this year.</p>

A fast-paced show, focusing on current events, social issues, sport and entertainment.

<p>A fast-paced show, focusing on current events, social issues, sport and entertainment.</p>

Advertisement